Tuberculosis in Hematopoietic Stem Cell Transplant Recipients

Literature on tuberculosis (TB) occurring in recipients of Hematopoietic Stem Cell Transplant (HSCT) is scanty even in countries where TB is common. Most reports of TB in HSCT patients were from ASIA, in fact the TB incidence ranging from 0.0014 (USA) to 16% (Pakistan). There are few reports of TB d...

Full description

Bibliographic Details
Main Authors: Ramos, Jéssica Fernandes, Batista, Marjorie Vieira, Costa, Silvia Figueiredo
Format: Online
Language:English
Published: Università Cattolica del Sacro Cuore 2013
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867227/
id pubmed-3867227
recordtype oai_dc
spelling pubmed-38672272013-12-20 Tuberculosis in Hematopoietic Stem Cell Transplant Recipients Ramos, Jéssica Fernandes Batista, Marjorie Vieira Costa, Silvia Figueiredo Review Article Literature on tuberculosis (TB) occurring in recipients of Hematopoietic Stem Cell Transplant (HSCT) is scanty even in countries where TB is common. Most reports of TB in HSCT patients were from ASIA, in fact the TB incidence ranging from 0.0014 (USA) to 16% (Pakistan). There are few reports of TB diagnosis during the first two weeks after HSCT; most of cases described in the literature occurred after 90 days of HSCT, and the lung was the organ most involved. The mortality ranged from 0 to 50% and is higher in allogeneic HSCT than in autologous. There is no consensus regarding the screening with tuberculin skin test or QuantiFERON-TB gold, primary prophylaxis for latent TB, and whether the epidemiologic query should be emphasized in developing countries with high prevalence of TB. Università Cattolica del Sacro Cuore 2013-11-04 /pmc/articles/PMC3867227/ /pubmed/24363876 http://dx.doi.org/10.4084/MJHID.2013.061 Text en This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Ramos, Jéssica Fernandes
Batista, Marjorie Vieira
Costa, Silvia Figueiredo
spellingShingle Ramos, Jéssica Fernandes
Batista, Marjorie Vieira
Costa, Silvia Figueiredo
Tuberculosis in Hematopoietic Stem Cell Transplant Recipients
author_facet Ramos, Jéssica Fernandes
Batista, Marjorie Vieira
Costa, Silvia Figueiredo
author_sort Ramos, Jéssica Fernandes
title Tuberculosis in Hematopoietic Stem Cell Transplant Recipients
title_short Tuberculosis in Hematopoietic Stem Cell Transplant Recipients
title_full Tuberculosis in Hematopoietic Stem Cell Transplant Recipients
title_fullStr Tuberculosis in Hematopoietic Stem Cell Transplant Recipients
title_full_unstemmed Tuberculosis in Hematopoietic Stem Cell Transplant Recipients
title_sort tuberculosis in hematopoietic stem cell transplant recipients
description Literature on tuberculosis (TB) occurring in recipients of Hematopoietic Stem Cell Transplant (HSCT) is scanty even in countries where TB is common. Most reports of TB in HSCT patients were from ASIA, in fact the TB incidence ranging from 0.0014 (USA) to 16% (Pakistan). There are few reports of TB diagnosis during the first two weeks after HSCT; most of cases described in the literature occurred after 90 days of HSCT, and the lung was the organ most involved. The mortality ranged from 0 to 50% and is higher in allogeneic HSCT than in autologous. There is no consensus regarding the screening with tuberculin skin test or QuantiFERON-TB gold, primary prophylaxis for latent TB, and whether the epidemiologic query should be emphasized in developing countries with high prevalence of TB.
publisher Università Cattolica del Sacro Cuore
publishDate 2013
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867227/
_version_ 1612039598071873536